Advertisement Ferring buys two Phase III ready orthobiologic products from BioSET - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Ferring buys two Phase III ready orthobiologic products from BioSET

Ferring Pharmaceuticals has acquired the assets of BioSurface Engineering Technologies (BioSET) including two Phase III ready orthobiologic product candidates designed to improve bone repair.

According to the company, the initial indications for AMPLEX and PREFIX to be investigated are fusion in foot/ankle and lumbar spine surgical procedures, respectively.

The two products are based on a biomimetic peptide designed to improve the body’s own natural mechanisms of bone repair.

Ferring president of the Executive Board and COO Michel Pettigrew said: "With the acquisition of the BioSET portfolio, Ferring intends to build on its growing success in orthopaedics.

"By developing new orthobiologic products for joint fusion, we will expand and diversify our offering to include innovative solutions for orthopaedic surgery."

Apart from AMPLEX and PREFIX, the company has also acquired a library of rationally designed biomimetic peptides intended for applications in bone and tissue repair.